Q2B26 Copenhagen | Gian Luca Anselmetti, Quantum Computing Scientist, Boehringer-Ingelheim

Q2B26 Copenhagen | Gian Luca Anselmetti, Quantum Computing Scientist, Boehringer-Ingelheim

by Gian Luca Anselmetti · View the channel on PSI

Formal & Physical Sciences Computing & Cybersecurity UYComputer scienceUYXNatural computing
🎙 Gian Luca Anselmetti 👥 6K 📅 October 12, 2026 ⏱ 20 min 👁 53 📄 expert opinion 🧭 2026-10-15
Available in: English (current) Français

Keywords

quantum computingdrug designHamiltonianfault tolerancequantum chemistry

Summary

Gian Luca Anselmetti, a quantum computing scientist at Boehringer-Ingelheim, presented a talk at Q2B26 Copenhagen on the progress of quantum computing for drug design. He outlined the team’s approach, focusing on fault-tolerant quantum computers and their potential to solve quantum chemistry problems more accurately than classical methods. He discussed the challenges of drug discovery, such as the vast chemical space and the need for accurate binding affinity predictions. The talk covered resource estimation for simulating enzymes like cytochrome P450, showing a reduction in runtime from three days to two hours through algorithmic improvements and compilation techniques. He emphasized the overhead of error correction and the amount of logical qubits required. Anselmetti highlighted open questions, including whether quantum computers can outperform classical approximations for real drugs and the need for algorithms beyond ground-state energy calculations. He mentioned a recent Google publication that matches his projected progress, but stressed that further improvements are needed for practical applications. The talk concluded with a Q&A about the feasibility of achieving order-of-magnitude resource reductions and the importance of developing more advanced quantum algorithms.

178 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk provides substantial value by presenting concrete resource estimates and algorithmic improvements from an industrial perspective, which is often scarce. Anselmetti argues convincingly that fault tolerance is necessary to surpass classical methods, and he supports this with detailed numbers and comparisons to classical techniques like coupled cluster. His argumentation is logical and well-structured, moving from the general drug design funnel to specific quantum chemistry methods and then to practical resource estimates. He acknowledges the limitations and open questions, which strengthens his credibility. The discussion on runtime reduction via Hamiltonian compression and compilation tricks is particularly insightful, offering a realistic view of what is achievable.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, as the talk is based on peer-reviewed work, including collaborations with Google and PsiQuantum, and references publications in reputable journals like Nature Physics. The speaker is transparent about the limitations and the tentative nature of the projections. The title accurately reflects the content, being a specific progress report. However, the talk relies primarily on the speaker’s own expertise and internal work; no external sources are cited beyond the conference website. The description provides a link to the Q2B conference, but no direct links to the mentioned papers are given, which is a minor weakness for verification.

221 words

Title / Content Match

The title accurately reflects the content: a talk about progress in quantum computing for drug design by a scientist from Boehringer-Ingelheim.

Quality & Reliability

8/10

Expert from a leading pharmaceutical company with peer-reviewed research, talk includes concrete technical details and references to publications, but no external verification within the talk itself.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • Q2B Conference — Conference website where the talk was presented, providing context for the venue and event.

Contribution & Novelties

The talk presents original industrial insights into the resource requirements for quantum computing in drug design, notably the reduction of runtime for simulating cytochrome P450 from three days to two hours through algorithmic and compilation improvements. This is a significant contribution to the field’s understanding of practical scalability. Anselmetti also raises the critical question of whether current drug molecules are sufficiently hard for quantum computers to outperform classical methods, which is a key research direction.

Pour aller plus loin :

  • Quantum computing — Overview of quantum computing principles, including qubits and superposition.
  • Quantum chemistry — The field focused on applying quantum mechanics to chemical systems, central to the talk.
  • Cytochrome P450 — The enzyme family discussed, important in drug metabolism.
  • Fault-tolerant quantum computer — Concepts behind error correction and fault tolerance, essential for the speaker’s arguments.

136 words

Radar Profile

The scores indicate a technically deep and information-rich presentation, with very high technical level and moderate reliability due to lack of external citations. The balanced scores across quantity and quality suggest a dense but credible talk, though the narrow focus may limit general applicability.

Reliability 8/10